The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has re‐evaluated the developmental toxicity of acetone. Available unpublished study reports and publications are described in detail. The maximum concentration at the work place (MAK value) of acetone is 500 ml/m 3 , based on the irritant effect and the state of health of volunteers. In a development toxicity study after inhalation exposure no teratogenic effects were found in the mouse up to 6600 ml/m 3 . The diversity of malformations was increased at 11 000 ml/m 3 in the rat, and there was a linear trend for variations of asymmetric sternebrae and delayed ossifications of the sternum. Reduced foetal weights were found in both rats and mice. The NOAEC for developmental toxicity in rats and mice is 2200 ml/m 3 ; the NAEC (no adverse effect concentration) could be even higher than 2200 ml/m 3 . As a greater diversity of malformations was observed in rat pups at concentrations that caused only slight maternal toxicity, and only a four‐fold margin lies between the NOAEC for developmental toxicity and the MAK value of 500 ml/m 3 , damage to the embryo or foetus cannot be excluded after exposure to concentrations at the level of 500 ml/m 3 and acetone is assigned to Pregnancy Risk Group B. In view of the NOAEC for developmental toxicity of 2200 ml/m 3 , prenatal toxicity is not to be expected at acetone concentrations of about 200 ml/m 3 or below, corresponding to the definition of Pregnancy Risk Group C.
MAK Value Documentation for Ethyl acrylate The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has re‐evaluated the maximum concentration at the workplace (MAK value) of ethyl acrylate of 5 ml/m 3 , considering all toxicity endpoints. Available unpublished study reports and publications are described in detail. The critical effect of ethyl acrylate is irritation of eye and nose in humans and the olfactory mucosa in rats and mice. The chronic NOAEC in rats is 5 ml/m 3 . Since 2014 the Commission uses an empirical approach to set MAK values for substances with critical effects on the upper respiratory tract or the eyes. Accordingly, the MAK value has to be lowered to 2 ml/m 3 , which is confirmed in a recent volunteer study with a NOAEC of 2.5 and a LOAEC of 5 ml ethyl acrylate/m 3 . As local effects are critical, the assignment to Peak Limitation Category I and the excursion factor of 2 are confirmed. Developmental toxicity studies with ethyl acrylate show that damage to the embryo or foetus is unlikely if the MAK value is observed, and the assignment to Pregnancy Risk Group C is retained. Ethyl acrylate is not genotoxic in vivo and not carcinogenic. Skin contact may contribute significantly to systemic toxicity and ethyl acrylate is designated with an “H” notation. The available data confirm that the substance is a skin sensitizer and the designation with “Sh” is retained. There are no data concerning the potential for respiratory sensitization.
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has derived a maximum concentration at the work place (MAK value) for calcium hydroxide, considering all toxicity endpoints. Available publications are described in detail. The critical effect of calcium hydroxide is irritation of eyes and upper airways. From studies in volunteers with calcium oxide, which is hydrolysed in aqueous media to calcium hydroxide, a MAK value of 1 mg/m 3 for the inhalable fraction is derived. Since local effects are critical, calcium hydroxide is assigned to Peak Limitation Category I and as there were no irritation effects after 20 minutes exposure to 2 mg/m 3 , an excursion factor of 2 is set. Studies with the read‐across calcium oxide show that damage to the embryo or foetus is unlikely when the MAK value for calcium hydroxide is observed, and the substance is assigned to Pregnancy Risk Group C. Calcium hydroxide is neither genotoxic nor carcinogenic. Skin contact is not expected to contribute significantly to systemic toxicity or to lead to sensitization.
MAK Value Documentation for Trimethylamine The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has re‐evaluated the maximum concentration at the work place (MAK value) of trimethylamine of 2 ml/m 3 , considering the endpoints local and systemic toxicity as well as developmental toxicity. Available publications are described in detail. Daily exposure of rats to trimethylamine for 14 days resulted in inflammation of the respiratory epithelium at 74 ml/m 3 , the lowest concentration tested. Since 2014, the Commission uses an empirical approach to set MAK values for substances with critical effects on the upper respiratory tract or the eyes. According to this approach, the MAK value would have to be lowered to 1 ml/m 3 . However, several data show, that the previous MAK value can be retained. Workers reported no irritation at 5 ml trimethylamine/m 3 . In addition cyclohexylamine and dimethylamine with a MAK value of 2 ml/m 3 are used as a read‐across due to similar alkalinity and RD 50 values, and in a recent volunteer study a NOAEC of 2 ml cyclohexylamine/m 3 is found. The MAK value will also protect from possible blue hazy vision which is caused by other tertiary amines since trimethylamine is assumed to be less effective than N,N‐dimethylethylamine with a MAK value of 2 ml/m 3 . The assignment is to Peak Limitation Category I, because local effects are critical, and the excursion factor of 2 is confirmed. Developmental toxicity studies with trimethylamine show that damage to the embryo or foetus is unlikely if the MAK value is observed, and the assignment to Pregnancy Risk Group C is retained.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.